Personalized Radiotherapy for Head and Neck Cancer
Author Information
Author(s): Courtney P. Travis, L. Santoso Milisuryani, Savjani Ricky R., K. Reddy Vishruth, Chai-Ho Wanxing, Velez Velez Maria A., J. Wong Deborah, Palodichuk Christy, Basehart T. Vincent, P. O’Connell Dylan, Cao Minsong, Telesca Donatello, Chin Robert K.
Primary Institution: University of California, Los Angeles
Hypothesis
We hypothesize that this radiotherapy regimen will lead to improved local tumor control compared with historical controls in patients undergoing palliative radiotherapy for head and neck cancer.
Conclusion
The study aims to evaluate the safety and efficacy of a new radiotherapy regimen for patients with head and neck cancer who cannot receive standard treatments.
Supporting Evidence
- Current palliative radiation therapy options can provide adequate symptom improvement but have limitations.
- Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) may improve local control and reduce toxicity.
- The study will evaluate the safety and efficacy of PULSAR in patients who cannot receive standard treatments.
Takeaway
This study is testing a new way to give radiation therapy to help people with head and neck cancer feel better, especially if they can't have regular treatments.
Methodology
This is a single-arm phase II study evaluating PULSAR with HyperArc© software for palliative treatment of head and neck cancer, involving 43 patients receiving radiation in five fractions.
Limitations
The study may not fully leverage online adaptive radiotherapy planning due to technology limitations.
Participant Demographics
Patients with de novo or recurrent, localized or metastatic head and neck cancer who are ineligible for or decline standard of care definitive treatments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website